---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-22-290244"
form_type: "8-K"
ticker: "CALC"
cik: "0001534133"
company_name: "CalciMedica, Inc."
filed_at: "2022-11-22T23:59:59+00:00"
generated_at: "2026-06-21T14:07:39.156352+00:00"
event_type: "m_and_a"
sentiment: "neutral"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# Graybug to merge with CalciMedica; combined company focused on Auxora for inflammatory diseases

## Summary
- Graybug holders to own ~29% of combined co; CalciMedica holders ~71% (based on $40M and $100M valuations).
- Combined co expected to have ~$35M cash at close, with runway into H2 2024; includes ~$10.3M private placement.
- Auxora Phase 2b AP data expected H2 2023; Phase 1/2 AAP data H1 2023; potential accelerated approval path.
- Rachel Leheny (CalciMedica CEO) to lead combined co; board 5 CalciMedica / 2 Graybug; close expected Q1 2023.

## SEC filing metadata
- accession: 0001193125-22-290244
- form_type: 8-K
- ticker: CALC
- cik: 0001534133
- company_name: CalciMedica, Inc.
- filed_at: 2022-11-22T23:59:59+00:00
- event_type: m_and_a
- sentiment: neutral
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 1.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1534133/000119312522290244/0001193125-22-290244-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1534133/000119312522290244/d403773d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-22-290244
- JSON: https://secwatch.observer/filing/0001193125-22-290244.json
- Plain text: https://secwatch.observer/filing/0001193125-22-290244.txt

## Key facts
- Material Agreements
  CalciMedica, Inc. entered into Agreement and Plan of Merger and Reorganization with CalciMedica, Inc. (effective 2022-11-21).
  - Action: entry
  - Agreement: merger
  - Counterparty: CalciMedica, Inc.
  - Effective: 2022-11-21
  source text: On November 21, 2022, Graybug Vision, Inc., a Delaware corporation (“ Graybug ”), entered into an Agreement and Plan of Merger and Reorganization (the “ Merger Agreement ”) with CalciMedica, Inc., a Delaware corporation (“ CalciMedica ”), a clinical-stage biopharmaceutical company focused on developing first-in-class therapies for serious inflammatory diseases with high unmet need, and Camaro Merger Sub, Inc., a Delaware corporation and wholly-owned subsidiary of Graybug (“ Merger Sub ”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1534133/000119312522290244/0001193125-22-290244-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.